Expression of long non-coding RNA linc-ITGB1 in breast cancer and its influence on prognosis and survival.
Long noncoding RNA linc-ITGB1 (linc-ITGB1) was reported to serve as a tumor promoter in breast cancer (BC). However, the clinical significance of linc-ITGB1 has not been reported. The present study aimed to determine the relationship between linc-ITGB1 expression and clinicopathological features and survival. qRT-PCR was used to quantify the expression levels of linc-ITGB1 in BC and adjacent non-cancerous breast tissues. The X2 test was performed to determine the associations between linc-ITGB expression and the clinicopathological characters. The overall survival time (OS) and disease-free survival (DFS) were collected by follow-up and analyzed by Kaplan-Meier analysis. Multivariate Cox regression analysis was used to identify the independent risk factors for BC. The results showed that linc-ITGB1 levels were lower in tumor tissues of BC patients in comparison to adjacent non-cancerous breast tissues (p < 0.001). Linc-ITGB1 expression was significantly associated with lymph node metastasis, pathological differentiation and TNM stage (all p < 0.05). Furthermore, Kaplan-Meier analysis demonstrated that high-linc-ITGB1 expression level was associated with poorer OS (p = 0.006) and DFS (p = 0.003). Cox proportional hazards risk analysis demonstrated that linc-ITGB1 was an independent predictor for both OS (p = 0.004) and DFS (p = 0.002) in BC. These results indicated, for the first time, that linc-ITGB1 be a potential biomarker in the prognosis of BC.